NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

Leber Hereditary Optic Neuropathy

Synonyms: LHON, Leber's Disease, Leber's Optic Atrophy, Leber's Optic Neuropathy

, BMedSci, MBBS, PhD, FRCPath, FRCOphth and , BMedSci, MBBS, PhD, FRCPath, FRCP, FMedSci.

Author Information

Initial Posting: ; Last Update: June 23, 2016.

Summary

Clinical characteristics.

Leber hereditary optic neuropathy (LHON) is characterized by bilateral, painless, subacute visual failure that develops during young adult life. Males are four to five times more likely than females to be affected. Affected individuals are usually entirely asymptomatic until they develop visual blurring affecting the central visual field in one eye; similar symptoms appear in the other eye an average of two to three months later. In about 25% of cases, visual loss is bilateral at onset. Visual acuity is severely reduced to counting fingers or worse in the majority of cases, and visual field testing shows an enlarging dense central or centrocecal scotoma. After the acute phase, the optic discs become atrophic. Significant improvement in visual acuity is rare and most persons qualify for registration as legally blind (visual acuity ≤20/200). Neurologic abnormalities such as postural tremor, peripheral neuropathy, nonspecific myopathy, and movement disorders have been reported to be more common in individuals with LHON than in the general population. Some individuals with LHON, usually women, may also develop a multiple sclerosis-like illness.

Diagnosis/testing.

The diagnosis of LHON is established in a proband with bilateral, painless, subacute visual failure that develops during young adult life and/or by the identification of one of three common mtDNA pathogenic variants (m.3460G>A in MT-ND1, m.11778G>A in MT-ND4, or m.14484T>C in MT-ND6) on molecular genetic testing.

Management.

Treatment of manifestations: Management of affected individuals is largely supportive, with the provision of visual aids, help with occupational rehabilitation, and registration with the relevant social services. ECG may reveal a pre-excitation syndrome in individuals harboring a mtDNA LHON-causing pathogenic variant; referral to cardiology can be considered and treatment for symptomatic individuals is the same as that in the general population. A multidisciplinary approach for those affected individuals with extraocular neurologic features (ataxia, peripheral neuropathy, nonspecific myopathy, and movement disorders) should be considered to minimize the functional consequences of these complications.

Prevention of primary manifestations: Treatment for raised intraocular pressure in individuals who have a LHON-causing pathogenic variant.

Agents/circumstances to avoid: Individuals harboring a mtDNA LHON-causing pathogenic variant should be strongly advised to moderate their alcohol intake and not to smoke. Avoiding exposure to other putative environmental triggers for visual loss, in particular industrial toxins and drugs with mitochondrial-toxic effects, also seems reasonable.

Genetic counseling.

Leber hereditary optic neuropathy is caused by pathogenic variants in mtDNA and transmitted by mitochondrial (maternal) inheritance. Genetic counseling for LHON is complicated by the gender- and age-dependent penetrance of the primary mtDNA LHON-causing pathogenic variants. The mother of a proband usually has the mtDNA pathogenic variant and may or may not have symptoms. In most cases a history of visual loss affecting maternal relatives at a young age is present, but up to 40% of cases are simplex (i.e., occur in a single individual in a family). A male (affected or unaffected) with a primary LHON-causing mtDNA pathogenic variant cannot transmit the variant to any of his offspring. A female (affected or unaffected) with a primary LHON-causing mtDNA pathogenic variant transmits the variant to all of her offspring. Prenatal diagnosis for mitochondrial pathogenic variants is possible if the variant in a family is known; however, accurate interpretation of a positive prenatal test result is difficult because the mtDNA mutational load in amniocytes and chorionic villi may not correspond to that of other fetal or adult tissues, and the presence of the mtDNA pathogenic variant does not predict the occurrence of disease, age of onset, severity, or rate of disease progression.

Diagnosis

Suggestive Findings

Leber hereditary optic neuropathy (LHON) should be suspected in individuals with the following ophthalmologic, extraocular, neuroimaging, biochemical, and family history findings:

Ophthalmologic

  • Bilateral, painless subacute visual failure that develops during young adult life
    • Visual acuity is severely reduced to counting fingers or worse in the majority of cases.
    • Visual field testing by kinetic or static perimetry shows an enlarging dense central or centrocecal scotoma.
  • Disk hyperemia, edema of the peripapillary retinal nerve fiber layer, retinal telangiectasia, and increased vascular tortuosity
    Note: Approximately 20% of affected individuals show no fundal abnormalities in the acute stage.
  • Optic disc atrophy
  • Electrophysiologic studies (pattern electroretinogram and visual evoked potentials) demonstrating optic nerve dysfunction and the absence of retinal disease

Extraocular

  • Neurologic abnormalities
    • Postural tremor
    • Peripheral neuropathy
    • Movement disorders
    • Multiple sclerosis-like illness
  • Nonspecific myopathy
  • Cardiac arrhythmias

Neuroimaging. Magnetic resonance imaging (MRI) is often normal, but may reveal white matter lesions and/or a high signal within the optic nerves [Matthews et al 2015].

Biochemical studies show respiratory chain defect that is more subtle than that seen in other mitochondrial genetic disorders. The m.3460G>A pathogenic variant in MT-ND1 is associated with the most severe biochemical phenotype (see Table 1).

Table 1.

Respiratory Chain Dysfunction in LHON

Mitochondrial DNA VariantIn VitroIn Vivo
Complex I ActivityRespiratory Rate 1MRS 1
m.3460G>A60%-80% less than controls30%-35%0%
m.11778G>A0%-50% less than controls30%-50%75%
m.14484T>C0%-65% less than controls10%-20%50%

See references in Man et al [2002].

MRS = magnetic resonance spectroscopy

1.

% of decrease relative to controls

Family history of similarly affected individuals is seen in up to 60% of probands. Note: Absence of a family history of LHON does not preclude the diagnosis.

Establishing the Diagnosis

The diagnosis of LHON is established in a proband with the ocular manifestations listed in Suggestive Findings and/or by the identification of one of three common mtDNA pathogenic variants on molecular genetic testing (see Table 2).

Molecular testing approaches can include targeted testing, a multi-gene panel, or complete mtDNA sequencing.

Targeted testing. Three common mtDNA pathogenic variants account for 90%-95% of LHON. Targeted analysis for one of these three variants should be performed first.

A multi-gene panel that includes the mitochondrial genes that encode subunits of NADH dehydrogenase, MT-ND1, MT-ND2, MT-ND4, MT-ND4L, MT-ND5, and MT-ND6, which are known to cause LHON (see Table 5 [pdf]) and other genes of interest (see Differential Diagnosis) may also be considered. Note: The genes included and the sensitivity of multi-gene panels vary by laboratory and over time.

Complete mtDNA sequencing may be considered if use of targeted testing and/or a multi-gene panel did not identify a pathogenic variant, clinical suspicion remains high, and there is no evidence of paternal transmission.

Table 2.

Molecular Genetic Testing Used in Leber Hereditary Optic Neuropathy (LHON)

Gene 1Proportion of LHON Attributed to Pathogenic Variants in This GeneProportion of Pathogenic Variants 2 Detected by Test Method
Targeted analysis for pathogenic variantsSequence analysis 3Gene-targeted deletion/duplication analysis 4
MT-ND4,
MT-ND6,
MT-ND1
~90% 5, 6See footnote 790% 6None reported 6
Select mitochondrial genes~10% 6, 810% 6None reported 6
1.
2.

See Molecular Genetics for information on allelic variants detected in this gene.

3.

Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.

4.

Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.

5.
6.
7.

The three most common pathogenic variants are: m.11778G>A (MT-ND4), accounting for approximately 70% of cases among northern European populations [Wallace et al 1988, Mackey et al 1996]; m.14484T>C (MT-ND6), most common among French Canadians as a result of a founder effect [Johns et al 1992a, Macmillan et al 1998]; and m.3460G>A (MT-ND1) [Howell et al 1992].

8.

Interpretation of test results. Heteroplasmy, a mixture of mutated and wild-type mtDNA in leukocytes, occurs in approximately 10%-15% of individuals with LHON [Smith et al 1993, Man et al 2003].

  • Heteroplasmy does not influence the sensitivity of molecular genetic testing for LHON because affected individuals generally have more than 70% mutated mtDNA in leukocytes, which is easily detected by standard techniques.
  • It is likely that the level of heteroplasmy may have a bearing on the risk of developing LHON in the asymptomatic individual and on the risk for transmission [Chinnery et al 2001]; however, no rigorous prospective studies have been performed to clarify this possibility.

Clinical Characteristics

Clinical Description

Leber hereditary optic neuropathy (LHON) typically presents in young adults as bilateral, painless, subacute visual failure. The peak age of onset in LHON is in the second and third decades of life, with 95% of those who lose their vision doing so before age 50 years. Very rarely, individuals first manifest LHON in the seventh and eighth decades of life [Dimitriadis et al 2014]. Males are four to five times more likely to be affected than females, but neither gender nor mutational status significantly influences the timing and severity of the initial visual loss.

In the presymptomatic phase, fundal abnormalities including peripapillary telangiectatic vessels and variable degrees of retinal nerve fiber layer edema have been previously documented; these can vary with time [Nikoskelainen 1994]. Using optical coherence tomography imaging, thickening of the temporal retinal nerve fiber layer was confirmed in clinically unaffected individuals with a LHON-causing mtDNA pathogenic variant, providing further evidence that the papillomacular bundle is particularly vulnerable in LHON [Savini et al 2005]. On more detailed investigation, some individuals with a LHON-causing mtDNA pathogenic variant can also exhibit subtle impairment of optic nerve function including: (a) loss of color vision affecting mostly the red-green system, (b) reduced contrast sensitivity, and (c) subnormal electroretinogram and visual evoked potential [Sadun et al 2006].

Affected individuals are usually entirely asymptomatic until they develop visual blurring affecting the central visual field in one eye (acute phase); similar symptoms appear in the other eye an average of two to three months later, so that both eyes are affected in the majority of cases within six months. Unilateral optic nerve involvement in LHON is exceptionally rare; if it is present, another underlying pathologic process should be actively excluded. In about 25% of cases, visual loss is bilateral at onset. The most characteristic feature is an enlarging central or centrocecal scotoma and as the field defect increases in size and density, visual acuity deteriorates to the level of counting fingers or worse. Following the nadir, visual acuity may improve; such improvement is more likely in individuals with the m.14484T>C pathogenic variant than in those with the m.11778G>A or m.3460G>A pathogenic variant (see Genotype-Phenotype Correlations).

Other positive prognostic factors have been identified including an earlier age of onset (<10 years), a subacute presentation with slow visual deterioration, and a relatively large optic disc [Barboni et al 2006, Ramos et al 2009].

The atrophic phase is characterized by optic atrophy (which typically develops within six weeks of the onset of visual loss) and a dense central or centrocecal scotoma. Most persons remain severely visually impaired and are within the legal requirements for blind registration [Kirkman et al 2009].

Other neurologic features associated with LHON. Some neurologic abnormalities (e.g., postural tremor, peripheral neuropathy, nonspecific myopathy, movement disorders, and Leigh syndrome) have been reported to be common in individuals with LHON [McFarland et al 2007, Martikainen et al 2016].

Some individuals with LHON, usually women, may develop a progressive multiple sclerosis (MS)-like illness. The pattern of visual loss in LHON-MS appears distinct from classic LHON, being marked by recurrent episodes of visual loss that can be associated with ocular pain, but with incomplete visual recovery and progression to legal blindness in half of all affected persons [Pfeffer et al 2013]. In addition to a severe bilateral optic neuropathy, these individuals manifest disseminated central nervous system demyelination, with characteristic periventricular white matter lesions and unmatched cerebrospinal fluid oligoclonal bands [Bhatti & Newman 1999, Horváth et al 2000, Palace 2009] (see Multiple Sclerosis Overview).

Cardiac conduction defects and LHON. A Finnish study showed an increased incidence of cardiac arrhythmias secondary to accessory pathways in association with LHON [Nikoskelainen 1994]; this finding has not been replicated in other populations [Bower et al 1992].

Genotype-Phenotype Correlations

Some broad categorization can be made with regard to specific LHON-causing pathogenic variants:

It must be emphasized that recovery of visual function in LHON, if it does occur, is usually incomplete. Reported visual recovery rates among persons with LHON are summarized in Table 3; the lifetime risk for visual failure in individuals with a homoplasmic primary LHON-causing pathogenic variant by sex and age is summarized in Table 4.

Table 3.

Visual Recovery Rates by Pathogenic Variant in Individuals with LHON

1.

Different criteria have been used to define visual recovery; the range partly reflects this variability.

2.

Although published reports would appear to indicate otherwise, the m.3460G>A pathogenic variant is generally accepted among experts as having the worst visual recovery rate [Author, personal communication].

Table 4.

Lifetime Risk for Visual Failure in Individuals with a Homoplasmic Primary LHON-Causing Mitochondrial DNA Pathogenic Variant by Study

Mitochondrial DNA Pathogenic VariantRisk of Developing SymptomsMedian Age at Onset (Males)Male/Female RatioReference
MalesFemales
m.3460G>A32%15%20 yrs4.3:1Nikoskelainen [1994]
m.3460G>A49%28%22 yrs1.7:1Man et al [2003]
m.11778G>A43%11%24 yrs3.7:1Harding et al [1995]
m.11778G>A51%9%22 yrs5.1:1Man et al [2003]
m.14484T>C47%8%20 yrs7.7:1Macmillan et al [1998]

A multiple sclerosis-like illness has been reported in association with all three primary mtDNA LHON-causing pathogenic variants (m.3460G>A, m.11778G>A, and m.14484T>C), but with a female bias [Pfeffer et al 2013].

Penetrance

LHON-causing mtDNA pathogenic variants are characterized by reduced penetrance. An individual can only develop LHON if a pathogenic mtDNA LHON-causing variant is present, but approximately 50% of males and 90% of females who harbor a primary LHON-causing mtDNA pathogenic variant do not develop blindness. It must be stressed that penetrance can vary markedly in different branches of the same family and between families harboring the same LHON-causing mtDNA pathogenic variants, which complicates genetic counseling at the individual level. Additional environmental and genetic factors interact with the primary mtDNA pathogenic variant and determine whether an individual ultimately develops optic nerve dysfunction and visual failure. The two most important risk factors for visual loss are sex and age (see Table 4) [Yu-Wai-Man et al 2009].

  • Age-related penetrance of LHON. The penetrance of LHON is age specific. The 95th centile for age at onset is 50 years for all three primary pathogenic variants. Thus, a clinically unaffected male age 50 years has less than a 1/20 chance of losing his vision [Man et al 2003].
  • Heteroplasmy. Many mitochondria (and thus many mtDNA molecules) are present in each cell. Some individuals with a pathogenic LHON-causing mtDNA variant have a mixture of mutated and wild-type species of mtDNA, a finding referred to as heteroplasmy. Heteroplasmy is present in 10%-15% of individuals with a LHON-causing mtDNA variant. In one study, individuals with a m.11778G>A pathogenic variant load of less than 75% in their leukocytes were unaffected [Smith et al 1993]. In a retrospective analysis of 17 families heteroplasmic for the m.11778G>A pathogenic variant, males with a mutational load greater than 60% in their leukocytes had an increased frequency of optic neuropathy than did those with lower mutational loads [Chinnery et al 2001]. However, quantifying the level of heteroplasmy for the purpose of presymptomatic testing is limited as the majority of individuals with a LHON-causing mtDNA variant are homoplasmic.

Anticipation

Anticipation has not been seen in LHON.

Nomenclature

In the past, LHON was sometimes referred to as Leber hereditary optic neuroretinopathy; this term is outdated and should not be used.

Prevalence

In the North East of England, 1:8,500 individuals were found to harbor a pathogenic LHON-causing variant; 1:31,000 had experienced visual loss as a result of LHON [Man et al 2003, Gorman et al 2015]. Fairly similar figures have been reported in other northern European populations, with a disease prevalence of 1:39,000 in the Netherlands and 1:50,000 in Finland [Spruijt et al 2006, Puomila et al 2007].

Differential Diagnosis

If the ophthalmologic assessment (including an assessment of visual acuity, color vision, visual fields, and electrophysiology) and molecular genetic testing leave any uncertainty about the diagnosis of Leber hereditary optic neuropathy (LHON), further investigations are appropriate to exclude other potentially reversible causes of bilateral optic neuropathy and to allow for the initiation of prompt treatment before visual loss becomes irreversible. Depending on the clinical presentation and evolution, autoantibody testing and an infectious or vasculitic screen may be warranted. A lumbar puncture should be performed when clinically indicated to evaluate for unmatched oligoclonal bands in suspected cases of demyelination or to exclude infectious and neoplastic causes. The appropriate neuroimaging modality should be requested and the films should ideally be reviewed with an experienced neuroradiologist.

Acute phase. A wide range of non-genetic causes of bilateral visual failure must be excluded during the acute phase.

Atrophic phase. If an individual is only seen at this stage, it can be difficult to exclude other possible causes of optic atrophy, especially if there is no clear maternal family history. In these cases, neuroimaging of the anterior visual pathways is mandatory while awaiting the results of molecular genetic testing.

Management

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with Leber hereditary optic neuropathy (LHON), the following evaluations are recommended:

  • Measurement of best corrected visual acuity
  • Assessment of visual fields with static or kinetic perimetry
  • ECG. Although a relatively rare finding, an ECG may reveal a pre-excitation syndrome in both symptomatic and asymptomatic individuals who have a LHON-causing mtDNA variant. Even when present, such an ECG finding does not necessitate further intervention in the absence of cardiac symptoms.
  • Screening for possible associated neurologic complications, which can further compound the visual impairment among individuals with LHON
  • Consultation with a clinical geneticist and/or genetic counselor

Treatment of Manifestations

Management of affected individuals is supportive and includes provision of visual aids, occupational rehabilitation, and registration with the relevant local social services.

A minority of individuals with LHON develop neurologic features including ataxia, peripheral neuropathy, nonspecific myopathy, and movement disorders. This group of affected individuals should be managed by a multidisciplinary team of physicians and allied professionals to minimize the functional consequences of these neurologic complications.

In those individuals who are found to have pre-excitation syndrome on ECG, referral to a cardiologist can be considered; treatment for symptomatic individuals with pre-excitation syndrome is the same as in the general population.

Prevention of Primary Manifestations

There is evidence that raised intraocular pressure could be a risk factor triggering visual loss in individuals at risk for developing LHON. Until further evidence becomes available, it is reasonable to set a lower threshold for initiating treatment for raised intraocular pressure in individuals with a LHON-causing variant given the possible deleterious consequences of raised intraocular pressure on mitochondrial function and retinal ganglion cell survival [Thouin et al 2013].

Surveillance

Ongoing surveillance of asymptomatic individuals harboring LHON-causing mtDNA variants is not necessary; however, they should be advised to seek immediate medical attention should they experience any visual disturbance.

The frequency of follow-up for affected individuals varies depending on the individual’s personal circumstances and the availability of healthcare locally.

Agents/Circumstances to Avoid

Individuals harboring established LHON-causing mtDNA variants should be strongly advised not to smoke and to moderate their alcohol intake, avoiding binge-drinking episodes. Although based largely on anecdotal evidence, avoidance of other environmental factors that have been implicated in precipitating visual loss in LHON (e.g., head trauma, industrial toxins, drugs with mitochondrial toxic effects) would seem reasonable.

Evaluation of Relatives at Risk

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Therapies Under Investigation

Idebenone. Small case series have reported that oral administration of idebenone (a short-chain synthetic benzoquinone; 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone) and/or vitamin supplementation (B12 and C) can accelerate visual recovery and improve final visual outcome in patients with LHON [Mashima et al 2000, Carelli et al 2001]. A subsequent report of two individuals with LHON showed no visual benefit from idebenone and multivitamin supplementation [Barnils et al 2007].

To address these conflicting anecdotal findings, a Phase II double-blind randomized placebo-controlled trial was conducted to investigate the efficacy, safety, and tolerability of oral idebenone in LHON: RHODOS (Rescue of Hereditary Optic Disease Outpatient Study). In total, 85 affected individuals harboring one of the three primary mtDNA LHON-causing variants (m.3460G>A, m.11778G>A, and m.14484T>C) were successfully enrolled in this multicenter study [Klopstock et al 2013]. Research subjects were assigned in a two-to-one randomization ratio to receive either idebenone (at a dose of 300 mg/3x/day) or placebo. This dose of idebenone was found to be safe with no significant drug-related adverse events. Affected individuals with discordant visual acuities (defined as a difference of >0.2 LogMAR between the two eyes) and at highest risk for further visual loss in the least affected eye were more likely to benefit from treatment with idebenone [Klopstock et al 2011].

In the follow-up study (RHODOS-OFU), the beneficial effect of six months of treatment with idebenone appeared to persist despite discontinuation of the active medication at the end of the trial [Klopstock et al 2013]. In a large retrospective study involving 103 individuals with LHON, 44 with visual loss of one year’s duration or less were treated with idebenone and followed up for at least five years. A greater proportion of those in the treated group recovered vision compared with the untreated group, and the most consistent factor associated with visual recovery was an early initiation of treatment during the acute phase of the disease process [Carelli et al 2011]. It must be stressed that idebenone will not completely reverse the significant damage already sustained to the optic nerve, but in those affected individuals who do respond, there is an increased rate and likelihood of visual recovery compared with the known natural history.

There is no evidence to support the prophylactic use of idebenone among asymptomatic individuals with LHON-causing mtDNA variants.

EPI-743. In an open-label study of five individuals with acute LHON treated within 90 days of disease conversion, the antioxidant α-tocotrienol-quinone (EPI-743), a vitamin E derivative, has shown early promise [Sadun et al 2012]. An adequately powered, double-blind, randomized placebo-controlled trial is needed to confirm the visual benefit of this agent in both acute and chronic LHON [Sadun et al 2012].

Gene therapy. Targeted gene therapy for LHON is being actively explored for affected individuals harboring the m.11778G>A pathogenic variant [Qi et al 2003, Qi et al 2004, Qi et al 2007, Ellouze et al 2008, Lam et al 2010]. Promising pre-clinical data based on in vitro and rodent models have resulted in the recent launch of pivotal clinical trials for affected individuals with the m.11778G>A pathogenic variant involving the intravitreal injection of a modified adeno-associated virus (AAV2) vector carrying the replacement MTND4 subunit (see ClinicalTrials.gov).

Hormone therapy. The marked male bias in LHON could reflect a protective influence of female sex hormones, and this hypothesis was recently investigated using LHON cybrid cell lines. Treatment with estrogens was found to reduce reactive oxygen species levels in these LHON cybrids, with increased activity of the antioxidant enzyme superoxide dismutase. These beneficial estrogenic effects translated into more efficient mitochondrial oxidative phosphorylation [Giordano et al 2011]. Further research is needed to determine whether females with a LHON-causing variant are at increased risk for visual loss in the perimenopausal period and following the onset of menopause.

Mitochondrial replacement. In vitro fertilization (IVF) techniques aimed at preventing the maternal transmission of mtDNA pathogenic variants from mother to child are being developed. Pronuclear transfer and metaphase II spindle transfer are the two approaches that are being investigated, and further experimental work to validate the safety and potential clinical applicability of these IVF strategies is currently ongoing [Tachibana et al 2009, Craven et al 2010, Chinnery et al 2014].

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

Leber hereditary optic neuropathy (LHON) is caused by pathogenic variants in mtDNA and it is strictly transmitted by mitochondrial (maternal) inheritance.

Risk to Family Members

Parents of a proband

  • The father of a proband is not at risk of having the mtDNA pathogenic variant.
  • The mother of a proband usually has the mtDNA pathogenic variant and may or may not have developed visual loss.
  • In approximately 60% of cases, a family history of visual loss affecting maternal relatives is present.
  • Up to 40% of individuals with LHON have no known family history of LHON. The explanation for apparently simplex cases may be absence of a comprehensive and/or reliable family history or, in rare cases, a de novo mtDNA pathogenic variant in the proband.

Sibs of a proband. The risk to sibs depends on the genetic status of the mother: if the mother has the mtDNA pathogenic variant, all sibs of a proband will inherit the variant and may or may not have symptoms (see Offspring of a proband).

Offspring of a proband

  • A male (affected or unaffected) with a primary LHON-causing mtDNA variant cannot transmit the variant to any of his offspring.
  • A female (affected or unaffected) with a primary LHON-causing mtDNA variant will transmit the variant to all of her offspring.
  • The presence of the mtDNA pathogenic variant does not predict the occurrence, age of onset, severity, or rate of progression of visual loss. See Genotype-Phenotype Correlations and Penetrance for information regarding the risk to individuals with a primary LHON-causing mtDNA variant of being affected.
  • If an affected female is heteroplasmic for the mtDNA LHON-causing variant, she may transmit a lower level of mutated mtDNA to her offspring, conferring a low disease risk [Chinnery et al 2001].

Other family members. The risk to other family members depends on the genetic status of the proband's mother: if the proband's mother has a mtDNA pathogenic variant, her sibs and mother are also at risk.

Related Genetic Counseling Issues

Penetrance. Genetic counseling for LHON is complicated by the gender- and age-dependent penetrance of the primary LHON-causing mtDNA variants. Large studies have established accurate risks for the m.11778G>A and m.14484T>C pathogenic variants (reviewed in Yu-Wai-Man et al [2009]). Confirming the genetic status of an individual at risk for one of these pathogenic variants who is seeking counseling allows for an accurate estimation of the risks, based on established age- and gender-specific penetrance data (see Genotype-Phenotype Correlations). Data for the m.3460G>A pathogenic variant are more limited. Similarly, counseling for the other pathogenic variants requires cautious extrapolation.

Testing of at-risk asymptomatic adult relatives of individuals with LHON is possible after molecular genetic testing has identified the specific pathogenic mtDNA variant in the family. Such testing should be performed in the context of formal genetic counseling. The presence of the pathogenic variant in leukocytes confers a lifetime risk, however, such testing is not useful in predicting age of onset, severity, or the rate of progression of visual loss in asymptomatic individuals. The most important factors determining risk are gender and age (see Genotype-Phenotype Correlations and Penetrance). For example, a male age 18 years has a lifetime risk of approximately 50% for LHON after a positive test result. The risk declines with age but, because loss of sight can occur at any age, the risk never falls to zero. In large, multi-generational LHON pedigrees, these risks were known before the advent of molecular genetic testing. In smaller families, it is important to confirm the genetic status because it is possible that a pathogenic variant is heteroplasmic in the affected individual or his mother, and it may not be present in every family member. It must be stressed that the penetrance can vary markedly in different branches of the same family and between families harboring the same LHON-causing mtDNA pathogenic variants.

Testing of asymptomatic individuals younger than age 18 years who are at risk for adult-onset disorders for which no treatment exists is not considered appropriate, primarily because it negates the autonomy of the child with no compelling benefit. Further, concern exists regarding the potential unhealthy adverse effects that such information may have on family dynamics, the risk of discrimination and stigmatization in the future, and the anxiety that such information may cause.

It is appropriate to consider testing symptomatic individuals regardless of age in a family with an established diagnosis of LHON.

For more information, see the National Society of Genetic Counselors position statement on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics policy statement: ethical and policy issues in genetic testing and screening of children.

Family planning

  • The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.
  • It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing and Preimplantation Genetic Diagnosis

Once a mtDNA LHON-causing variant in the mother has been identified, prenatal testing and preimplantation genetic diagnosis [Sallevelt et al 2013] for a pregnancy at increased risk for LHON are possible options.

Accurate interpretation of a positive prenatal test result is difficult for the following reasons:

  • The majority of mothers will be homoplasmic for the mtDNA LHON-causing variant. For mothers who are heteroplasmic, the mtDNA mutational load in amniocytes and chorionic villi may not correspond to that of other fetal or adult tissues due to mitotic segregation.
  • The presence of the mtDNA LHON-causing variant does not predict the occurrence, age of onset, severity, or the rate of progression of visual loss in this mitochondrial genetic disorder. See Genotype-Phenotype Correlations for information regarding the risk to individuals with a primary LHON-causing mtDNA variant of being affected.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A.

Leber Hereditary Optic Neuropathy: Genes and Databases

Data are compiled from the following standard references: gene from HGNC; chromosome locus, locus name, critical region, complementation group from OMIM; protein from UniProt. For a description of databases (Locus Specific, HGMD) to which links are provided, click here.

Table B.

OMIM Entries for Leber Hereditary Optic Neuropathy (View All in OMIM)

516000COMPLEX I, SUBUNIT ND1; MTND1
516001COMPLEX I, SUBUNIT ND2; MTND2
516003COMPLEX I, SUBUNIT ND4; MTND4
516004COMPLEX I, SUBUNIT ND4L; MTND4L
516005COMPLEX I, SUBUNIT ND5; MTND5
516006COMPLEX I, SUBUNIT ND6; MTND6
516020CYTOCHROME b OF COMPLEX III; MTCYB
516050CYTOCHROME c OXIDASE III; MTCO3
516060ATP SYNTHASE 6; MTATP6
535000LEBER OPTIC ATROPHY

Molecular Genetic Pathogenesis

See Mitochondrial Disorders Overview.

The ocular pathology in Leber hereditary optic neuropathy (LHON) is limited to the retinal ganglion cell layer with sparing of the retinal pigment epithelium and photoreceptor layers. There is marked cell body and axonal degeneration, with associated demyelination, that extends to the lateral geniculate bodies. A number of pathologic factors have been implicated, including a reduction in the amount of ATP being produced by the mitochondrial respiratory chain (Table 1), impaired glutamate transport, and increased levels of reactive oxygen species production, all of which ultimately trigger retinal ganglion cell death via an apoptotic mechanism [Danielson et al 2002, Beretta et al 2004, Zanna et al 2005, Levin 2015].

Although LHON has a well-defined clinical and molecular genetic phenotype, the pathophysiology is complex and the selective vulnerability of retinal ganglion cells in this mitochondrial disorder remains unexplained [Yu-Wai-Man et al 2011]. It is also not known why otherwise entirely healthy individuals suddenly develop optic nerve dysfunction in young adulthood. The incomplete penetrance and predilection for males to lose vision also imply that additional genetic and/or environmental factors must modulate the phenotypic expression of LHON (see Genotype-Phenotype Correlations and Penetrance). Alternatively, the gender bias could also result from a combination of subtle anatomic, hormonal, and/or physiologic variations between males and females.

Benign allelic variants. See Mitochondrial Disorders Overview.

Pathogenic allelic variants. See Mitochondrial Disorders Overview.

Many different mtDNA variants have been associated with LHON in the literature and in numerous online databases (www.mitomap.org). Some of these changes are rare polymorphisms and some are common sequence variants in the normal population. Great caution should therefore be exercised in attributing significance to a "rare" LHON-causing mtDNA variant found in a single affected individual or family.

See Table 5 (pdf) for a list of mtDNA variants for which strong evidence of pathogenicity exists.

See Table 6 (pdf) for a list of putative pathogenic variants.

Normal gene product. See Mitochondrial Disorders Overview.

Abnormal gene product. See Mitochondrial Disorders Overview.

References

Published Guidelines/Consensus Statements

  1. Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available online. 2013. Accessed 6-15-16. [PubMed: 23428972]
  2. National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset disorders. Available online. 2012. Accessed 6-15-16.

Literature Cited

  1. Achilli A, Iommarini L, Olivieri A, Pala M, Hooshiar Kashani B, Reynier P, La Morgia C, Valentino ML, Liguori R, Pizza F, Barboni P, Sadun F, De Negri AM, Zeviani M, Dollfus H, Moulignier A, Ducos G, Orssaud C, Bonneau D, Procaccio V, Leo-Kottler B, Fauser S, Wissinger B, Amati-Bonneau P, Torroni A, Carelli V. Rare primary mitochondrial DNA mutations and probable synergistic variants in Leber's hereditary optic neuropathy. PLoS One. 2012;2012;7:e42242. [PMC free article: PMC3411744] [PubMed: 22879922]
  2. Barboni P, Savini G, Valentino ML, La Morgia C, Bellusci C, De Negri AM, Sadun F, Carta A, Carbonelli M, Sadun AA, Carelli V. Leber's hereditary optic neuropathy with childhood onset. Invest Ophthalmol Vis Sci. 2006;2006;47:5303–9. [PubMed: 17122117]
  3. Barnils N, Mesa E, Munoz S, Ferrer-Artola A, Arruga J. Arch Soc Esp Oftalmol. 2007;82:377–80. [Response to idebenone and multivitamin therapy in Leber's hereditary optic neuropathy] [PubMed: 17573650]
  4. Beretta S, Mattavelli L, Sala G, Tremolizzo L, Schapira AH, Martinuzzi A, Carelli V, Ferrarese C. Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines. Brain. 2004;127:2183–92. [PubMed: 15342361]
  5. Bhatti MT, Newman NJ. A multiple sclerosis-like illness in a man harboring the mtDNA 14484 mutation. J Neuroophthalmol. 1999;19:28–33. [PubMed: 10098545]
  6. Blakely EL, de Silva R, King A, Schwarzer V, Harrower T, Dawidek G, Turnbull DM, Taylor RW. LHON/MELAS overlap syndrome associated with a mitochondrial MTND1 gene mutation. Eur J Hum Genet. 2005;13:623–7. [PubMed: 15657614]
  7. Bower SP, Hawley I, Mackey DA. Cardiac arrhythmia and Leber's hereditary optic neuropathy. Lancet. 1992;1992;339:1427–8. [PubMed: 1350847]
  8. Carelli V, La Morgia C, Valentino ML, Rizzo G, Carbonelli M, De Negri AM, Sadun F, Carta A, Guerriero S, Simonelli F, Sadun AA, Aggarwal D, Liguori R, Avoni P, Baruzzi A, Zeviani M, Montagna P, Barboni P. Idebenone treatment in Leber's hereditary optic neuropathy. Brain. 2011;134:e188. [PubMed: 21810891]
  9. Carelli V, Valentino ML, Liguori R, Meletti S, Vetrugno R, Provini F, Mancardi GL, Bandini F, Baruzzi A, Montagna P. Leber's hereditary optic neuropathy (LHON/11778) with myoclonus: report of two cases. J Neurol Neurosurg Psychiatry. 2001;71:813–6. [PMC free article: PMC1737658] [PubMed: 11723211]
  10. Chinnery PF, Andrews RM, Turnbull DM, Howell NN. Leber hereditary optic neuropathy: Does heteroplasmy influence the inheritance and expression of the G11778A mitochondrial DNA mutation? Am J Med Genet. 2001;98:235–43. [PubMed: 11169561]
  11. Chinnery PF, Craven L, Mitalipov S, Stewart JB, Herbert M, Turnbull DM. The challenges of mitochondrial replacement. PloS Genet. 2014;10:e1004315. [PMC free article: PMC3998882] [PubMed: 24762741]
  12. Craven L, Tuppen HA, Greggains GD, Harbottle SJ, Murphy JL, Cree LM, Murdoch AP, Chinnery PF, Taylor RW, Lightowlers RN, Herbert M, Turnbull DM. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature. 2010;465:82–5. [PMC free article: PMC2875160] [PubMed: 20393463]
  13. Danielson SR, Wong A, Carelli V, Martinuzzi A, Schapira AH, Cortopassi GA. Cells bearing mutations causing Leber's hereditary optic neuropathy are sensitized to Fas-Induced apoptosis. J Biol Chem. 2002;277:5810–5. [PubMed: 11741983]
  14. De Vries DD, Went LN, Bruyn GW, Scholte HR, Hofstra RM, Bolhuis PA, van Oost BA. Genetic and biochemical impairment of mitochondrial complex I activity in a family with Leber hereditary optic neuropathy and hereditary spastic dystonia. Am J Hum Genet. 1996;58:703–11. [PMC free article: PMC1914692] [PubMed: 8644732]
  15. Dimitriadis K, Leonhardt M, Yu-Wai-Man P, Kirkman MA, Korsten A, De Coo IF, Chinnery PF, Klopstock T. Leber's hereditary optic neuropathy with late disease onset: clinical and molecular characteristics of 20 patients. Orphanet J Rare Dis. 2014;2014;9:158. [PMC free article: PMC4212093] [PubMed: 25338955]
  16. Ellouze S, Augustin S, Bouaita A, Bonnet C, Simonutti M, Forster V, Picaud S, Sahel JA, Corral-Debrinski M. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet. 2008;83:373–87. [PMC free article: PMC2556433] [PubMed: 18771762]
  17. Giordano C, Montopoli M, Perli E, Orlandi M, Fantin M, Ross-Cisneros FN, Caparrotta L, Martinuzzi A, Ragazzi E, Ghelli A, Sadun AA, d'Amati G, Carelli V. Oestrogens ameliorate mitochondrial dysfunction in Leber's hereditary optic neuropathy. Brain. 2011;134:220–34. [PMC free article: PMC3025718] [PubMed: 20943885]
  18. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, Alston CL, Feeney C, Horvath R, Yu-Wai-Man P, Chinnery PF, Taylor RW, Turnbull DM, McFarland R. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol. 2015;77:753–9. [PMC free article: PMC4737121] [PubMed: 25652200]
  19. Gropman A, Chen TJ, Perng CL, Krasnewich D, Chernoff E, Tifft C, Wong LJ. Variable clinical manifestation of homoplasmic G14459A mitochondrial DNA mutation. Am J Med Genet A. 2004;124A:377–82. [PubMed: 14735585]
  20. Harding AE, Sweeney MG, Govan GG, Riordan-Eva P. Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation. Am J Hum Genet. 1995;57:77–86. [PMC free article: PMC1801226] [PubMed: 7611298]
  21. Horváth R, Abicht A, Shoubridge EA, Karcagi V, Rózsa C, Komoly S, Lochmüller H. Leber's hereditary optic neuropathy presenting as multiple sclerosis- like disease of the CNS. J Neurol. 2000;247:65–7. [PubMed: 10701903]
  22. Howell N, McCullough D, Bodis-Wollner I. Molecular genetic analysis of a sporadic case of Leber hereditary optic neuropathy. Am J Hum Genet. 1992;50:443–6. [PMC free article: PMC1682448] [PubMed: 1734726]
  23. Jia X, Li S, Xiao X, Guo X, Zhang Q. Molecular epidemiology of mtDNA mutations in 903 Chinese families suspected with Leber hereditary optic neuropathy. J Hum Genet. 2006;51:851–6. [PubMed: 16972023]
  24. Johns DR, Heher KL, Miller NR, Smith KH. Leber's hereditary optic neuropathy. Clinical manifestations of the 14484 mutation. Arch Ophthalmol. 1993;111:495–8. [PubMed: 8470982]
  25. Johns DR, Neufeld MJ, Park RD. An ND-6 mitochondrial DNA mutation associated with Leber hereditary optic neuropathy. Biochem Biophys Res Commun. 1992a;187:1551–7. [PubMed: 1417830]
  26. Johns DR, Smith KH, Miller NR. Leber's hereditary optic neuropathy. Clinical manifestations of the 3460 mutation. Arch Ophthalmol. 1992b;110:1577–81. [PubMed: 1444915]
  27. Jun AS, Brown MD, Wallace DC. A mitochondrial DNA mutation at nucleotide pair 14459 of the NADH dehydrogenase subunit 6 gene associated with maternally inherited Leber hereditary optic neuropathy and dystonia. Proc Natl Acad Sci U S A. 1994;91:6206–10. [PMC free article: PMC44167] [PubMed: 8016139]
  28. Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock T, Griffiths PG, Hudson G, Chinnery PF, Yu-Wai-Man P. Quality of life in patients with leber hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2009;50:3112–5. [PubMed: 19255150]
  29. Klopstock T, Metz G, Yu-Wai-Man P, Büchner B, Gallenmüller C, Bailie M, Nwali N, Griffiths PG, von Livonius B, Reznicek L, Rouleau J, Coppard N, Meier T, Chinnery PF. Persistence of the treatment effect of idebenone in Leber's hereditary optic neuropathy. Brain. 2013;136:e230. [PMC free article: PMC3572931] [PubMed: 23388409]
  30. Klopstock T, Yu-Wai-Man P, Dimitriadis K, Rouleau J, Heck S, Bailie M, Atawan A, Chattopadhyay S, Schubert M, Rummey C, Metz G, Leinonen M, Griffiths PG, Meier T, Chinnery PF. A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy. Brain. 2011;134:2677–86. [PMC free article: PMC3170530] [PubMed: 21788663]
  31. Lam BL, Feuer WJ, Abukhalil F, Porciatti V, Hauswirth WW, Guy J. Leber hereditary optic neuropathy gene therapy clinical trial recruitment: year 1. Arch Ophthalmol. 2010;128:1129–35. [PMC free article: PMC3220055] [PubMed: 20837795]
  32. Lam BL, Feuer WJ, Schiffman JC, Porciatti V, Vandenbroucke R, Rosa PR, Gregori G, Guy J. Trial end points and natural history in patients with G11778A Leber hereditary optic neuropathy : preparation for gene therapy clinical trial. JAMA Ophthalmol. 2014;2014;132:428–36. [PMC free article: PMC4266137] [PubMed: 24525545]
  33. Levin LA. Superoxide generation explains common features of optic neuropathies associated with cecocentral scotomas. J Neuroophthalmol. 2015;35:152–60. [PMC free article: PMC4581581] [PubMed: 25985432]
  34. Lightowlers RN, Taylor RW, Turnbull DM. Mutations causing mitochondrial disease: What is new and what challenges remain? Science. 2015;349:1494–9. [PubMed: 26404827]
  35. Mackey DA, Oostra RJ, Rosenberg T, Nikoskelainen E, Bronte-Stewart J, Poulton J, Harding AE, Govan G, Bolhuis PA, Norby S. Primary pathogenic mtDNA mutations in multigeneration pedigrees with Leber hereditary optic neuropathy. Am J Hum Genet. 1996;59:481–5. [PMC free article: PMC1914749] [PubMed: 8755941]
  36. Macmillan C, Kirkham T, Fu K, Allison V, Andermann E, Chitayat D, Fortier D, Gans M, Hare H, Quercia N, Zackon D, Shoubridge EA. Pedigree analysis of French Canadian families with T14484C Leber's hereditary optic neuropathy. Neurology. 1998;50:417–22. [PubMed: 9484365]
  37. Man PY, Griffiths PG, Brown DT, Howell N, Turnbull DM, Chinnery PF. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet. 2003;72:333–9. [PMC free article: PMC379226] [PubMed: 12518276]
  38. Man PY, Turnbull DM, Chinnery PF. Leber hereditary optic neuropathy. J Med Genet. 2002;39:162–9. [PMC free article: PMC1735056] [PubMed: 11897814]
  39. Martikainen MH, Ng YS, Gorman GS, Alston CL, Blakely EL, Schaefer AM, Chinnery PF, Burn DJ, Taylor RW, McFarland R, Turnbull DM. Clinical, genetic, and radiological features of extrapyramidal movement disorders in mitochondrial disease. JAMA Neurol. 2016;73:668–74. [PubMed: 27111573]
  40. Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuroophthalmol. 2000;20:166–70. [PubMed: 11001192]
  41. Mashima Y, Yamada K, Wakakura M, Kigasawa K, Kudoh J, Shimizu N, Oguchi Y. Spectrum of pathogenic mitochondrial DNA mutations and clinical features in Japanese families with Leber's hereditary optic neuropathy. Curr Eye Res. 1998;17:403–8. [PubMed: 9561832]
  42. Matthews L, Enzinger C, Fazekas F, Rovira A, Ciccarelli O, Dotti MT, Filippi M, Frederiksen JL, Giorgio A, Küker W, Lukas C, Rocca MA, De Stefano N, Toosy A, Yousry T, Palace J. MAGNIMS Network. (2015) MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis. J Neurol Neurosurg Psychiatry. 2015;86:537–42. [PMC free article: PMC4413690] [PubMed: 25053773]
  43. McFarland R, Chinnery PF, Blakely EL, Schaefer AM, Morris AA, Foster SM, Tuppen HA, Ramesh V, Dorman PJ, Turnbull DM, Taylor RW. Homoplasmy, heteroplasmy, and mitochondrial dystonia. Neurology. 2007;69:911–6. [PubMed: 17724295]
  44. McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol. 2010;9:829–40. [PubMed: 20650404]
  45. Newman NJ, Lott MT, Wallace DC. The clinical characteristics of pedigrees of Leber's hereditary optic neuropathy with the 11778 mutation. Am J Ophthalmol. 1991;111:750–62. [PubMed: 2039048]
  46. Nikoskelainen EK. Clinical picture of LHON. Clin Neurosci. 1994;2:115–20.
  47. Palace J. Multiple sclerosis associated with Leber's Hereditary Optic Neuropathy. J Neurol Sci. 2009;286:24–7. [PubMed: 19800080]
  48. Pfeffer G, Burke A, Yu-Wai-Man P, Compston DA, Chinnery PF. Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations. Neurology. 2013;81:2073–81. [PMC free article: PMC3863351] [PubMed: 24198293]
  49. Puomila A, Hamalainen P, Kivioja S, Savontaus ML, Koivumaki S, Huoponen K, Nikoskelainen E. Epidemiology and penetrance of Leber hereditary optic neuropathy in Finland. Eur J Hum Genet. 2007;15:1079–89. [PubMed: 17406640]
  50. Qi X, Lewin AS, Hauswirth WW, Guy J. Suppression of complex I gene expression induces optic neuropathy. Ann Neurol. 2003;53:198–205. [PubMed: 12557286]
  51. Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J. SOD2 gene transfer protects against optic neuropathy induced by deficiency of complex I. Ann Neurol. 2004;56:182–91. [PubMed: 15293270]
  52. Qi X, Sun L, Hauswirth WW, Lewin AS, Guy J. Use of mitochondrial antioxidant defenses for rescue of cells with a Leber hereditary optic neuropathy-causing mutation. Arch Ophthalmol. 2007;125:268–72. [PubMed: 17296905]
  53. Ramos CV, Bellusci C, Savini G, Carbonelli M, Berezovsky A, Tamaki C, Cinoto R, Sacai PY, Moraes-Filho MN, Miura HM, Valentino ML, Iommarini L, De Negri AM, Sadun F, Cortelli P, Montagna P, Salomao SR, Sadun AA, Carelli V, Barboni P. Association of optic disc size with development and prognosis of Leber's hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2009;50:1666–74. [PubMed: 19098324]
  54. Sadun AA, Chicani CF, Ross-Cisneros FN, Barboni P, Thoolen M, Shrader WD, Kubis K, Carelli V, Miller G. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol. 2012;69:331–8. [PubMed: 22410442]
  55. Sadun AA, Salomao SR, Berezovsky A, Sadun F, Denegri AM, Quiros PA, Chicani F, Ventura D, Barboni P, Sherman J, Sutter E, Belfort R Jr, Carelli V. Subclinical carriers and conversions in Leber hereditary optic neuropathy: a prospective psychophysical study. Trans Am Ophthalmol Soc. 2006;104:51–61. [PMC free article: PMC1809912] [PubMed: 17471325]
  56. Sallevelt SC, Dreesen JC, Drüsedau M, Spierts S, Coonen E, van Tienen FH, van Golde RJ, de Coo IF, Geraedts JP, de Die-Smulders CE, Smeets HJ. Preimplantation genetic diagnosis in mitochondrial DNA disorders: challenge and success. J Med Genet. 2013;50:125–32. [PubMed: 23339111]
  57. Savini G, Barboni P, Valentino ML, Montagna P, Cortelli P, De Negri AM, Sadun F, Bianchi S, Longanesi L, Zanini M, Carelli V. Retinal nerve fiber layer evaluation by optical coherence tomography in unaffected carriers with Leber's hereditary optic neuropathy mutations. Ophthalmology. 2005;112:127–31. [PubMed: 15629832]
  58. Smith KH, Johns DR, Heher KL, Miller NR. Heteroplasmy in Leber's hereditary optic neuropathy. Arch Ophthalmol. 1993;111:1486–90. [PubMed: 8240102]
  59. Spruijt L, Kolbach DN, de Coo RF, Plomp AS, Bauer NJ, Smeets HJ, de Die-Smulders CE. Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. Am J Ophthalmol. 2006;141:676–82. [PubMed: 16564802]
  60. Spruijt L, Smeets HJ, Hendrickx A, Bettink-Remeijer MW, Maat-Kievit A, Schoonderwoerd KC, Sluiter W, de Coo IF, Hintzen RQ. A MELAS-associated ND1 mutation causing leber hereditary optic neuropathy and spastic dystonia. Arch Neurol. 2007;64:890–3. [PubMed: 17562939]
  61. Tachibana M, Sparman M, Sritanaudomchai H, Ma H, Clepper L, Woodward J, Li Y, Ramsey C, Kolotushkina O, Mitalipov S. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature. 2009;461:367–72. [PMC free article: PMC2774772] [PubMed: 19710649]
  62. Tarnopolsky MA, Baker SK, Myint T, Maxner CE, Robitaille J, Robinson BH. Clinical variability in maternally inherited leber hereditary optic neuropathy with the G14459A mutation. Am J Med Genet A. 2004;124A:372–6. [PubMed: 14735584]
  63. Thouin A, Griffiths PG, Hudson G, Chinnery PF, Yu-Wai-Man P. Raised intraocular pressure as a potential risk factor for visual loss in leber hereditary optic neuropathy. PLoS One. 2013;8:e63446. [PMC free article: PMC3646743] [PubMed: 23667621]
  64. Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AM, Elsas LJ, Nikoskelainen EK. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science. 1988;242:1427–30. [PubMed: 3201231]
  65. Watanabe M, Mita S, Takita T, Goto Y, Uchino M, Imamura S. Leber's hereditary optic neuropathy with dystonia in a Japanese family. J Neurol Sci. 2006;243:31–4. [PubMed: 16380132]
  66. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies - Disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011;30:81–114. [PMC free article: PMC3081075] [PubMed: 21112411]
  67. Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J Med Genet. 2009;46:145–58. [PMC free article: PMC2643051] [PubMed: 19001017]
  68. Yu-Wai-Man P, Turnbull DM, Chinnery PF. Leber hereditary optic neuropathy. J Med Genet. 2002;39:162–9. [PMC free article: PMC1735056] [PubMed: 11897814]
  69. Zanna C, Ghelli A, Porcelli AM, Martinuzzi A, Carelli V, Rugolo M. Caspase-independent death of Leber's hereditary optic neuropathy cybrids is driven by energetic failure and mediated by AIF and Endonuclease G. Apoptosis. 2005;10:997–1007. [PubMed: 16151635]

Suggested Reading

  1. Yu-Wai-Man P, Votruba M, Moore AT, Chinnery PF. Treatment strategies for inherited optic neuropathies: past, present and future. Eye. 2014;28:521–37. [PMC free article: PMC4017118] [PubMed: 24603424]

Chapter Notes

Revision History

  • 23 June 2016 (ma) Comprehensive update posted live
  • 19 September 2013 (me) Comprehensive update posted live
  • 19 April 2012 (cd/pc) Revision: prenatal testing no longer listed in GeneTests Laboratory Directory; addition to therapies (EPI-743)
  • 7 July 2011 (me) Comprehensive update posted live
  • 10 March 2008 (me) Comprehensive update posted to live Web site
  • 3 October 2005 (pc) Revision: mitochondrial gene MTND2 added
  • 12 April 2005 (me) Comprehensive update posted to live Web site
  • 7 March 2003 (me) Comprehensive update posted to live Web site
  • 14 January 2002 (pc) Author revisions
  • 27 August 2001 (pc) Author revisions
  • 26 October 2000 (me) Review posted to live Web site
  • May 2000 (pc) Original submission
Copyright © 1993-2016, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.

GeneReviews® chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (http://www.genereviews.org/) and copyright (© 1993-2016 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the GeneReviews® Copyright Notice and Usage Disclaimer. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.

For more information, see the GeneReviews® Copyright Notice and Usage Disclaimer.

For questions regarding permissions or whether a specified use is allowed, contact: ude.wu@tssamda.

Bookshelf ID: NBK1174PMID: 20301353

Views

  • PubReader
  • Print View
  • Cite this Page
  • Disable Glossary Links

Tests in GTR by Condition

Related information

  • MedGen
    Related information in MedGen
  • OMIM
    Related OMIM records
  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...